Instrument Inactif

Autres langues Forest Laboratories, Inc.

Actions

US3458381064

Produits pharmaceutiques

Cours en clôture NYSE Autres places de cotation
- ^USD	-

28/04/14	Bank of America : Wall Street ouvre en hausse, les pharmaceutiques en vue	RE
28/04/14	Wall Street ouvre en hausse, les pharmaceutiques en vue	RE

Autres langues

17/11/16	Devisen: Euro fällt zum USD weiter - Hinweise auf US-Zinserhöhung belasten
30/06/14	Forest Laboratories : Actavis and Forest Receive U.S. FTC Clearance for Actavis’ Proposed Acquisition of Forest
30/06/14	Forest Laboratories : Actavis and Forest Announce Preliminary Stockholder Merger Consideration Election Results
23/06/14	Forest Laboratories : Announces Positive Topline Results from Three Phase III Trials for Vilazodone in the Treatment of Generalized Anxiety Disorder (GAD)
23/06/14	Forest Laboratories : Actavis and Forest Laboratories Announce Appointment of C. David Nicholson, PhD to lead Actavis Global Brands Research and Development
20/06/14	Forest Laboratories : to Present Cariprazine Data at the International College of Neuropsychopharmacology World Congress
18/06/14	Forest Laboratories : Obtains Six Months U.S. Pediatric Exclusivity for NAMENDA® and NAMENDA XR®
17/06/14	Forest Laboratories : COPD Foundation Releases Groundbreaking COPE Survey Results: Low Patient Awareness About COPD Exacerbations Poses Barrier to Effective Management
12/06/14	Forest Laboratories : Announces Receipt of Requisite Consents and Expiration of Consent Solicitations for Certain of its Senior Notes
10/06/14	Forest Laboratories : Announces Intention to Continue Marketing Both NAMENDA® TABLETS and Once-Daily NAMENDA XR® Into the Fall of 2014
09/06/14	Forest Laboratories : Extends Expiration Time of Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
30/05/14	Forest Laboratories : Announces Publication in The Lancet of Pivotal Phase III Hypertension Trial of the Fixed-Dose Combination of Nebivolol/Valsartan
22/05/14	Forest Laboratories : Commences Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
16/05/14	Forest Laboratories : to Present Data about Aclidinium, Aclidinium/Formoterol Combination, and Roflumilast at the American Thoracic Society International Conference
16/05/14	Forest Laboratories : to Present Nebivolol/Valsartan Fixed-Dose Combination Data at the American Society of Hypertension Annual Scientific Meeting
13/05/14	Forest Laboratories : Prestigious Recognitions, Financial Results, Presentations, Study Analysis, and SEC Filings - Analyst Notes on WellPoint, NPS Pharma, Novartis, Cigna and Forest
06/05/14	Actavis : Factbox - M&A frenzy transforming global pharma
06/05/14	Actavis : M&A frenzy in healthcare sector
02/05/14	Forest Laboratories : to Present Data about Levomilnacipran and Vilazodone at the American Psychiatric Association 167th Annual Meeting
01/05/14	Forest Laboratories : Ironwood and Forest to Present Linaclotide Data at Digestive Disease Week® 2014
29/04/14	Forest Laboratories : Reports Fiscal Year Fourth Quarter 2014
29/04/14	Forest Laboratories : Acquisition of Furiex Pharmaceuticals, Inc. by Forest Laboratories, Inc. May Not Be in Shareholders' Best Interests
28/04/14	Forest Laboratories : FURIEX INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Furiex Pharmaceuticals
28/04/14	Forest Laboratories : Joins ConvergeHEALTH by Deloitte's Rapid Learning Network in Collaboration with Intermountain Healthcare to Support Insights into Optimal Patient Care
28/04/14	Forest Laboratories : Furiex Pharmaceuticals (FURX) Shareholder Alert - Andrews & Springer LLC Is Seeking More Cash for Shareholders of Furiex Pharmaceuticals, Inc.